The US FDA has started a fresh review of Astellas' zolbetuximab, trying to become the first claudin (CLDN) 18.2-targeting drug to reach the US market, after turning it down earlier this year.

Caledonia Investments Plc (LON:CLDN – Get Free Report) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 3,793.30 ($49.11 ...